Protein Kinase Inhibitors Concept

subject area of

• 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty  Academic Article
• 4-phenylbutyrate and valproate treatment attenuates the progression of atherosclerosis and stabilizes existing plaques  Academic Article
• 8-isoprostaglandin E2 activates Ca2+-dependent K+ current via cyclic AMP signaling pathway in murine renal artery  Academic Article
• BCR–ABL1 transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase  Academic Article
• A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours  Academic Article
• A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer  Academic Article
• A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177  Academic Article
• A Small Molecule Discrimination Map of the Antibiotic Resistance Kinome  Academic Article
• A lentiviral vector‐based insertional mutagenesis screen identifies mechanisms of resistance to MAPK inhibitors in melanoma  Academic Article
• A novel inhibitor of Chlamydophila pneumoniae protein kinase D (PknD) inhibits phosphorylation of CdsD and suppresses bacterial replication  Academic Article
• A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191  Academic Article
• A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer  Academic Article
• A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer  Academic Article
• A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group  Academic Article
• A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium  Academic Article
• A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium  Academic Article
• A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors  Academic Article
• A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study  Academic Article
• A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer  Academic Article
• A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients  Academic Article
• ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis  Academic Article
• Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis  Academic Article
• Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma  Academic Article
• Akt isoform specific effects in ovarian cancer progression  Academic Article
• Allosteric linkers in cAMP signalling  Academic Article
• An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma  Academic Article
• An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy  Academic Article
• Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data  Academic Article
• Bacterial Peptidoglycan Stimulates Adipocyte Lipolysis via NOD1  Academic Article
• Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck  Academic Article
• Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation  Academic Article
• CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor–based regimen versus a cni-based regimen: a systematic review and meta-analysis of randomized, controlled trials  Academic Article
• Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium  Academic Article
• Canadian Consensus Recommendations on the Management of MET-Altered NSCLC  Academic Article
• Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer  Academic Article
• Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era  Academic Article
• Cardiovascular Safety Of Nintedanib In Subgroups By Cardiovascular Risk At Baseline In The Tomorrow And Inpulsis Trials  Conference Paper
• Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?  Academic Article
• Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance  Academic Article
• Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non–Small-Cell Lung Cancer in a Publicly Funded Health Care System  Academic Article
• Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials  Academic Article
• Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study  Academic Article
• Checkpoint inhibitor-associated autoimmunity  Academic Article
• Chronic opioids regulate K_ATP channel subunit Kir6.2 and carbonic anhydrase I and II expression in rat adrenal chromaffin cells via HIF-2α and protein kinase A  Academic Article
• Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients  Academic Article
• Control of oxygen free radical formation from mitochondrial complex I: roles for protein kinase A and pyruvate dehydrogenase kinase  Academic Article
• Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials  Academic Article
• Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective  Academic Article
• Current Incidence and Outcomes of Gastrointestinal Mesenchymal Tumors Including Gastrointestinal Stromal Tumors  Academic Article
• Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial  Academic Article
• Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib  Academic Article
• Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis  Academic Article
• Determination of soluble CAMP-dependent protein kinase activity in guinea-pig tracheal smooth muscle  Academic Article
• Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors  Academic Article
• EPIDERMAL GROWTH FACTOR-MEDIATED ACTIVATION OF THE MAP KINASE CASCADE RESULTS IN ALTERED EXPRESSION AND FUNCTION OF ABCG2 (BCRP)  Academic Article
• Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial  Academic Article
• Effects of PKB/Akt inhibitors on insulin-stimulated lipogenesis and phosphorylation state of lipogenic enzymes in white adipose tissue  Academic Article
• Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis  Academic Article
• Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline  Academic Article
• Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome  Academic Article
• Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol  Academic Article
• Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy  Academic Article
• Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice  Academic Article
• Gender andBCR-ABLtranscript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia  Academic Article
• Glycosyltransferases and Glycosaminoglycans in Bleomycin and Transforming Growth Factor-β1–Induced Pulmonary Fibrosis  Academic Article
• Guanosine Protects Glial Cells Against 6-Hydroxydopamine Toxicity  Academic Article
• High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells  Academic Article
• Hyperosmotic stress induces Rho/Rho kinase/LIM kinase-mediated cofilin phosphorylation in tubular cells: key role in the osmotically triggered F-actin response  Academic Article
• Hypoxia-Induced Lactate Dehydrogenase Expression and Tumor Angiogenesis  Academic Article
• Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy  Academic Article
• Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors  Academic Article
• Inhibition of Aminoglycoside Antibiotic Resistance Enzymes by Protein Kinase Inhibitors  Academic Article
• Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial  Academic Article
• Inhibition of sporulation, glycopeptide antibiotic production and resistance in Streptomyces toyocaensis NRRL 15009 by protein kinase inhibitors  Academic Article
• Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin  Academic Article
• Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.  Academic Article
• Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors  Academic Article
• Kinase inhibitors for cancer alter metabolism, blood glucose, and insulin  Academic Article
• Kinase inhibitors modulate huntingtin cell localization and toxicity  Academic Article
• Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia  Academic Article
• Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience  Academic Article
• Low salt concentrations activate AMP-activated protein kinase in mouse macula densa cells  Academic Article
• Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis  Academic Article
• Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009  Academic Article
• Mechanisms linking diabetes mellitus to the development of atherosclerosis: a role for endoplasmic reticulum stress and glycogen synthase kinase-3This paper is one of a selection of papers published in this Special Issue, entitled Young Investigator's Forum.  Conference Paper
• Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia  Academic Article
• Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators  Academic Article
• Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition  Academic Article
• Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE)  Academic Article
• Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases  Academic Article
• Nintedanib in Progressive Fibrosing Interstitial Lung Diseases  Academic Article
• Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial  Academic Article
• Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial  Academic Article
• Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance  Academic Article
• Optimal duration of imatinib treatment/deep molecular response for treatment‐free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial  Academic Article
• Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review  Academic Article
• Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer  Academic Article
• Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts  Academic Article
• Outcomes of children with chronic myeloid leukemia: A population‐based cohort study  Academic Article
• Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC  Academic Article
• PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma  Academic Article
• PKC-β1 Mediates Glucose-Induced Akt Activation and TGF-β1 Upregulation in Mesangial Cells  Academic Article
• PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer  Academic Article
• Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis  Academic Article
• Panax quinquefolium saponin combined with dual antiplatelet drugs inhibits platelet adhesion to injured HUVECs via PI3K/AKT and COX pathways  Academic Article
• Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children  Academic Article
• Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors  Academic Article
• Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies  Academic Article
• Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma  Conference Paper
• Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)  Academic Article
• Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis  Academic Article
• Polo-Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice  Academic Article
• Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors  Academic Article
• Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives  Academic Article
• Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases  Academic Article
• Predicting response to EGFR-tyrosine kinase inhibitors among diverse ancestries: Just way too polymorphic  Academic Article
• Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib  Academic Article
• Progressive Transforming Growth Factor β1–induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor  Academic Article
• Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies  Academic Article
• Protein kinase R-like endoplasmic reticulum kinase and glycogen synthase kinase-3α/β regulate foam cell formation  Academic Article
• Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma  Academic Article
• Quizartinib for the treatment of acute myeloid leukemia  Academic Article
• RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice  Academic Article
• Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520  Academic Article
• Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma  Academic Article
• Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo  Academic Article
• Real-time fluorogenic kinase assay using protein as substrate  Academic Article
• Regulation of IL-17A responses in human airway smooth muscle cells by Oncostatin M  Academic Article
• Response to ‘Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors’  Academic Article
• Reversible Cabozantinib-Induced Cardiomyopathy  Academic Article
• Role of α-Helical Coiled-coil Interactions in Receptor Dimerization, Signaling, and Adaptation during Bacterial Chemotaxis  Academic Article
• Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma  Academic Article
• Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America  Academic Article
• Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors  Academic Article
• Severe Bronchorrhea in a Patient with Bronchioloalveolar Carcinoma  Academic Article
• Simultaneous Inhibition Assay for Human and Microbial Kinases via MALDI-MS/MS  Academic Article
• Sirolimus and mTORC1: centre stage in the story of what makes muscles bigger?  Academic Article
• Skeletal muscle metabolism is unaffected by DCA infusion and hyperoxia after onset of intense aerobic exercise  Academic Article
• Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)  Academic Article
• Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study  Conference Paper
• Structure-guided optimization of protein kinase inhibitors reverses aminoglycoside antibiotic resistance  Academic Article
• Superoxide anion mediates angiotensin II-induced potentiation of contractile response to sympathetic stimulation  Academic Article
• Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results  Academic Article
• Synthesis and Biological Activity of a Focused Library of Mitogen-activated Protein Kinase Phosphatase Inhibitors  Academic Article
• Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma  Academic Article
• Targeted therapy for metastatic renal cell carcinoma  Academic Article
• Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how?  Academic Article
• The Antibiotic Resistome: A Guide for the Discovery of Natural Products as Antimicrobial Agents  Academic Article
• The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group  Academic Article
• The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA)  Academic Article
• The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis  Academic Article
• The inhibition of endocytosis affects HDL-lipid uptake mediated by the human scavenger receptor class B type I  Academic Article
• The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis  Academic Article
• Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia  Academic Article
• Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials  Academic Article
• Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline  Academic Article
• Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update  Academic Article
• Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?  Academic Article
• Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update  Academic Article
• Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?  Academic Article
• Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review  Academic Article
• Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease  Academic Article
• Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia  Academic Article
• Upregulation of MMP-13 via Runx2 in the stromal cell of Giant Cell Tumor of Bone  Academic Article
• Vemurafenib-induced radiation recall dermatitis: case report and review of the literature. - PubMed - NCBI  Article
• β2 integrin–derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis  Academic Article